The effect of luseogliflozin on epicardial fat accumulation in obese patients with type 2 diabetes

The effect of luseogliflozin on epicardial fat accumulation in obese patients with type 2 diabetes - SGLT2 inhibitor and ectopic fat in T2DM

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019072

Enrollment

Registered

2015-11-15

Start date

2015-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

luseogliflozin 2.5 mg for 12 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetic patients with BMI equal to or greater than 25.0 kg/m2 and HbA1c 6.5-9.0%

Exclusion criteria

Exclusion criteria: Patients who are taking SGLT2 inhibitors Patients with insulin treatment Patients with active infection, malignancy, severe liver or renal diseases Patients who are unable to figure out the consent due to dementia or impairment of consciousness Pregnant women, lactating woman, women who are planning to get pregnant Patients whose treatment for diabetes were changed 3 months prior to baseline evaluation

Design outcomes

Primary

Measure	Time frame
The change of epicardial fat volume at 12 weeks	—

Countries

Japan

Contacts

Public ContactRyotaro Bouchi

Tokyo Medical and Dental University Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences

bouchi.mem@tmd.ac.jp03-3813-6111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026